Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;100(7):e275-9.
doi: 10.3324/haematol.2015.124305. Epub 2015 Mar 20.

Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

Julio Finalet Ferreiro  1 , Julie Morscio  2 , Daan Dierickx  3 , Lukas Marcelis  2 , Gregor Verhoef  3 , Peter Vandenberghe  1 , Thomas Tousseyn  2 , Iwona Wlodarska  4
Affiliations

Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

Julio Finalet Ferreiro et al. Haematologica. 2015 Jul.
No abstract available

Keywords: 11q; Burkitt lymphoma; PTLD; post-transplant lymphoproliferative disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Genomic and transcriptomic data on PT-mBL. (A) Partial karyotype of case 5 (c5) and case 6 (c6) showing chromosome 11 abnormalities and FISH images of both derivative chromosomes painted with WCP11 (green) and WCP8 (red) (case 5), and WCP18 (red) (case 6). The aberrations were eventually described as der(11)(11pter->11q23.3::11q23.3->11q13::8q22q24.3) and der(11)t(11;18)(q23.3;q12), respectively. Note (inverted) duplication of 11q13q23.3 in case 5 and a normal appearance of this region in case 6. (B) Chromosomal view of chromosome 11q23q24 and imbalances identified by array CGH analysis in cases 5–7. Gained regions are highlighted in red-scale (increased intensity reflects an increased amplification level), while lost regions are marked in green. Note a variable level of 11q23.3 gain, a common loss of 11q24qter and the defined MGR (~4 Mb) and MLR (~13.5 Mb). (C) Examples of interphase FISH analysis performed in case 5 (a) and case 6 (b, c). The applied probes include the 11q-MGR/MLR FISH assay (a) (b), and two probes from the duplicated (RP11-284O21-SpectrumOrange) and amplified (RP11-784K23-SpectrumGreen; Online Supplementary Figure S2) area in case 6 (c). Note the duplicated and amplified red/11q23.3 signal in (a) and (c), respectively, and loss of the green/11q24 signal in both cases. In (c), note two red and five green signals in the cluster, illustrating various levels of gain within the MGR. (D) Hierarchical clustering of mBL cases using the dysregulated genes located in the MGR and MLR. (E) Interaction network found by Ingenuity Pathway Analysis involving genes targeted by the 11q-gain/loss aberration (bold edges). Solid and interrupted lines represent direct and indirect interactions, respectively. Notably, most of the interactions in this network are direct protein-protein interactions. The molecules with blue and green edges are encoded by MGR- and MLR-associated genes, respectively. The data obtained by comparison of cases 5–7 (PT-mBL with the 11q-gain/loss pattern) (11q+/−) by cases 1–4 (PT-MYC-translocation-positive mBL) [(t(MYC)] were overlaid in this network. Molecules which are down- and up-regulated in cases with 11q+/− when compared to cases with t(MYC) are filled in green and red, respectively.
See this image and copyright information in PMC

References

    1. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–2442. - PubMed
    1. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–2430. - PubMed
    1. Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187–1198. - PMC - PubMed
    1. Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433–2440. - PubMed
    1. Morscio J, Dierickx D, Ferreiro JF, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013; 13(5):1305–1316. - PubMed

Publication types

MeSH terms

Supplementary concepts